Shingo Nakamura
Direktor/Vorstandsmitglied bei REGiMMUNE Corp.
Aktive Positionen von Shingo Nakamura
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Shingo Nakamura
Ehemalige bekannte Positionen von Shingo Nakamura
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PRISM BioLab Co., Ltd.
PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Shingo Nakamura
MIT Sloan School of Management | Masters Business Admin |
Stanford University | Graduate Degree |
Waseda University | Undergraduate Degree |
Statistik
International
Japan | 4 |
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 2 |
Masters Business Admin | 1 |
Graduate Degree | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
PRISM BioLab Co., Ltd.
PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Health Technology |
- Börse
- Insiders
- Shingo Nakamura
- Erfahrung